Canada Peptide Guide
Home › Growth hormone
Growth hormone

Growth hormone secretagogues (GHRH analogs and GHRPs)

Peptides and one non-peptide (MK-677) that push the body to release more growth hormone. Almost none are authorized in Canada.

7 peptides0 authorized in Canada7 not authorized / other
Growth hormone peptides: illustration
CJC-1295 peptide illustrationCJC-1295A long-acting analog of growth hormone-releasing hormone (GHRH). Small human studies exist; it was never approved.…Not authorized in CanadaIpamorelin peptide illustrationIpamorelinA growth hormone-releasing peptide described in 1998 as the first selective GH secretagogue. Never approved; Health…Not authorized in CanadaSermorelin peptide illustrationSermorelinA shortened form of natural GHRH, reviewed in 1999 for use in children with growth hormone deficiency. We found no…Not authorized in CanadaTesamorelin peptide illustrationTesamorelinA GHRH analog studied and approved for excess abdominal fat in people with HIV-associated lipodystrophy. Its Canadian…Not currently marketed in CanadaGHRP-2 and GHRP-6 peptide illustrationGHRP-2 and GHRP-6Synthetic growth hormone-releasing peptides whose study led to the discovery of the natural hormone ghrelin. Not…Not authorized in CanadaHexarelin peptide illustrationHexarelinA potent GH-releasing peptide. In a 16-week human study its effect faded with continued use and body composition didn't…Not authorized in CanadaMK-677 (Ibutamoren) peptide illustrationMK-677 (Ibutamoren)MK-677 is often lumped in with peptides, but it is an oral non-peptide drug that acts on the ghrelin receptor. A…Not authorized in Canada

Evidence at a glance

How many peptides in this category reach each level of human evidence (our rating, see each page for sources).

Large randomized trials0
Some randomized trials1
Small human studies5
Cell & animal only1

Status and evidence table

PeptideCanada statusHuman evidence
CJC-1295Not authorized in Canada Limited: small or low-quality human studies
IpamorelinNot authorized in Canada Very limited: almost all animal or cell studies
SermorelinNot authorized in Canada Limited: small or low-quality human studies
TesamorelinNot currently marketed in Canada Moderate: some randomized human trials, specific uses (HIV-associated abdominal fat)
GHRP-2 and GHRP-6Not authorized in Canada Limited: small or low-quality human studies
HexarelinNot authorized in Canada Limited: small or low-quality human studies
MK-677 (Ibutamoren)Not authorized in Canada Limited: small or low-quality human studies; one trial stopped for a safety signal
Status reflects Health Canada's peptide pages, its April 2026 advisory and the Drug Product Database as checked on November 10, 2026. Authorized products carry an 8-digit DIN (drugs) or NPN (natural health products).